2016
Docetaxel in Advanced and Castration Resistant Prostate Cancer
Petrylak D, Hafez N. Docetaxel in Advanced and Castration Resistant Prostate Cancer. 2016, 77-92. DOI: 10.1007/978-3-319-31341-2_6.Peer-Reviewed Original ResearchResistant prostate cancerProstate cancerMetastatic castrate-resistant prostate cancerCastrate-resistant metastatic diseaseMetastatic castrate-resistant diseaseCastration-resistant prostate cancerCastrate-resistant prostate cancerResistant metastatic diseaseCastrate-resistant diseasePrimary chemotherapeutic agentStandard of careDocetaxel useTaxane cabazitaxelMetastatic diseaseDocetaxel efficacyRandomized trialsResistant diseaseLocal diseaseSuperior survivalDocetaxelChemotherapeutic agentsCancerDiseaseCorticosteroidsCabazitaxel
1999
Refractory disease, new horizons and patient–physician relationships
Glode L, Petrylak D. Refractory disease, new horizons and patient–physician relationships. Prostate Cancer And Prostatic Diseases 1999, 2: 19-20. PMID: 12496852, DOI: 10.1038/sj.pcan.4500272.Peer-Reviewed Original ResearchMore cost-effective careRole of chemotherapyDisease-free intervalPhase III trialsUse of PSACost-effective careProstate cancer cellsPatient-physician relationshipAdvanced diseasePain controlIII trialsRefractory diseaseNumerous new targetsFree intervalProstate cancerTreatment endpointSurrogate endpointsBiologic understandingCancer cellsDisease targetsEndpointNew targetsGrowth factor interactionsChemotherapyDisease